This review provides a comprehensive overview of future therapeutic strategies for ALK-p, ALK inhibitor-naïve advanced NSCLC with CNS metastases, mechanisms underlying acquired resistance, and strategies to overcome this challenge. This evidence concerns the gene ALK and non-small cell lung carcinoma.